Post-Market Feasibility Study of the Tenon Medical CATAMARAN™ SI Joint Fusion System

Prospective, Multi-Center, Single Arm Post-Market Feasibility Study of the Tenon Medical CATAMARAN™ SI Joint Fusion System

The purpose of this study is to evaluate the outcomes of patients with sacroiliac joint pain treated with the CATAMARAN SI Joint Fusion System.

Study Overview

• Status: Recruiting
• Conditions: Sacroiliac Joint Disruption; Degenerative Sacroiliitis
• Intervention / Treatment: Device: CATAMARAN SI Joint Fusion System

Detailed Description

This is a multi-center post-market study to evaluate the clinical outcomes of patients with sacroiliac joint disruptions or degenerative sacroiliitis treated with the CATAMARAN SI Joint Fusion System.

• Study Type: Interventional
• Enrollment (Estimated): 50
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Calvin Lincé; Phone Number: (510)274-7483; Email: clince@linceconsulting.com

Study Locations

• United States
  • Idaho
    • Coeur d'Alene, Idaho, United States, 83815
      • Recruiting
      • Northwest Specialty Hospital
      • Contact: Elisa Maples; Email: elisa.maples@nwsh.com
      • Principal Investigator: Roland Kent, MD
  • Indiana
    • Muncie, Indiana, United States, 47304
      • Recruiting
      • Comprehensive Pain and Spine Specialists
      • Contact: Erika Stogsdill; Email: ehuffman@majorhospital.org
      • Principal Investigator: Andrew T Trobridge, MD
  • Kentucky
    • Louisville, Kentucky, United States, 40241
      • Recruiting
      • Vitality Pain Centers
      • Contact: Drew Beacham; Email: dbeacham@vitalitypain.com
      • Principal Investigator: Timothy J Beacham, MD
  • Minnesota
    • Duluth, Minnesota, United States, 55805
      • Recruiting
      • Orthopedic Associates of Duluth
      • Contact: Athena Davies; Email: adavies@twu.edu
      • Principal Investigator: Mathew Davies, MD
  • Missouri
    • Chesterfield, Missouri, United States, 63017
      • Recruiting
      • St. Louis Pain Consultants
      • Principal Investigator: Anne Christopher, MD
      • Contact: Olayinka Idowu; Email: olayinka.idowu@stl-pain.com
  • Utah
    • Saint George, Utah, United States, 84790
      • Recruiting
      • St. George Orthopedic Spine
      • Principal Investigator: Mark Stouffer, MD, FAAOS

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Diagnosis of sacroiliac joint disruption or degenerative sacroiliitis based on ALL of the following:

  • Patient has pain at or close to the posterior superior iliac spine (PSIS) with possible radiation into buttocks, posterior thigh or groin and can point with a single finger to the location of pain (Fortin Finger Test), and
  • Patient has at least 3 of 5 physical examination maneuvers specific for SI joint pain (Fabers, Compression, Distraction,Thigh thrust, Gaenslen's test, and/or Sacral thrust test), and
  • Patient has improvement in lower back pain VAS of at least 50% of the pre injection VAS after fluoroscopic controlled injection of local anesthetic into affected SI joint(s) (including previous documented test <6 months ago)
• Patient has failed conservative care (non-surgical) > 6 months
• Patient has a pre-operative Oswestry Disability Index score > 30%
• Patient has a pre-operative SI joint pain score of > 50 on a 0-100 mm visual analog scale (VAS)
• Patient, or authorized representative, signs a written Informed Consent form to participate in the study
• Patient is willing and able to complete study follow-up requirements

Exclusion Criteria:

• Planned bi-lateral SI joint fixation
• Severe lower back pain due to other causes, such as lumbar disc degeneration, lumbar disc herniation, lumbar spondylolisthesis, lumbar spinal stenosis, lumbar facet degeneration, and lumbar vertebral body fracture (this is done by physical exam, medical history, and MRI/CT/X-ray as required)
• Other known sacroiliac pathology such as: sacral dysplasia, inflammatory sacroiliitis (e.g., ankylosing spondylitis or other HLA- associated spondyloarthropathy), tumor, acute fracture, crystal arthropathy
• History of recent (<1 year) fracture of the pelvis with documented malunion, non-union of sacrum or ilium or any type of internal fixation of the pelvic ring
• Severe osteoporosis
• Paget's disease, osteomalacia, osteomalacia or other metabolic bone disease
• Any condition or anatomy that makes treatment with the CATAMARAN SI Joint Fusion System infeasible including deformity
• Known allergy to titanium or titanium alloys
• Morbid obesity
• Active malignancy: a history of any invasive malignancy (except non-melanoma skin cancer), unless the subject has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least five years
• Patient has systemic infection or active infection at the treatment site
• Chronic rheumatologic condition (e.g., rheumatoid arthritis)
• Patient has uncontrolled diabetes
• Patient is currently receiving or seeking worker's compensation, disability remuneration, and/or involved in injury litigation
• Prominent neurologic condition that would interfere with physical therapy
• Patient is pregnant or wishes to become pregnant in the next two years
• Patient is not likely to comply with the follow-up evaluation schedule
• Patient is participating in a clinical trial of another investigational drug or device in which the primary endpoint has not occurred
• Patient has a psychiatric disease (e.g., schizophrenia, major depression, personality disorders) that could interfere with study participation
• Known or suspected drug or alcohol abuse
• Patient is a prisoner or a ward of the state

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: CATAMARAN SI Joint Fusion System; Placement of the Catamaran Fixation Device	Device: CATAMARAN SI Joint Fusion System; Placement of the Catamaran Fixation Device

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of subjects that meet the definition of Subject Success at 6 months post-procedure	Change from baseline in VAS SI joint pain score to be reduced by at least 20 mm, Lack of device-related serious adverse events, Absence of neurologic worsening related to the sacral spine compared to baseline (unless attributable to a concurrent medical condition or other cause unrelated to the device and/ or study procedure), and Absence of surgical re-intervention (removal, revision, reoperation, or supplemental fixation) for SI joint pain.	6 months post procedure

Collaborators and Investigators

• Sponsor: Tenon Medical

Study record dates

Study Major Dates

• Study Start (Actual): November 14, 2022
• Primary Completion (Estimated): January 1, 2025
• Study Completion (Estimated): January 1, 2026

Study Registration Dates

• First Submitted: November 14, 2022
• First Submitted That Met QC Criteria: November 21, 2022
• First Posted (Actual): December 1, 2022

Study Record Updates

• Last Update Posted (Actual): March 20, 2024
• Last Update Submitted That Met QC Criteria: March 18, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Joint Diseases; Musculoskeletal Diseases; Arthritis; Sacroiliitis
• Other Study ID Numbers: PTL015

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No